OTC-To-Rx Switch: Barrier Expects Zimycan Trial Data To Boost NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Barrier Therapeutics expects to amend Zimycan NDA with Phase III study in Candida-associated diaper dermatitis by year-end. Firm hopes to revive Johnson & Johnson’s attempted OTC topical antifungal as sole prescription option.